Waldencast announces conclusion of SEC investigation Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in…
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1…
Austin Accident Lawyer Podcast Talks Car and Truck Accidents and Insurance Claims
“Austin Accident Lawyer” Andrew Traub shares how his firm has helped their clients get past…
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
Company Provides Comprehensive Clinical Update from Phase 1/2 Trial Tuspetinib Continues to Deliver Single Agent…
Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate…
Interim data from phase III study presented at ASH 2022 show Hemlibra achieved meaningful bleed control in infants from birth
The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis)…
Roche’s subcutaneous crovalimab given every four weeks achieves disease control in people with PNH, a life-threatening blood condition
The phase III COMMODORE 3 study of crovalimab met primary endpoints of transfusion avoidance and…
Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting
— Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed…
Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual Meeting and Exposition
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and…
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
Oral presentation at American Society of Hematology (ASH) Annual Meeting highlights continued favorable safety and…
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022
Updated MCL and CLL data from the ongoing Phase 1/2 study of zilovertamab and ibrutinib…
Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
Data from REDIRECT establish that AFM13 monotherapy is effective in the treatment of relapsed/refractory peripheral…
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose…
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
AFM13 in combination with NK cells shows very high overall and complete response rates in…
Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)
Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in…
Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI®▼ (teclistamab) in Combination with DARZALEX® (daratumumab) Subcutaneous (SC) Formulation and Lenalidomide in Relapsed or Refractory Multiple Myeloma
Initial Phase 1b study results show clinical activity with immune-based triplet therapy regimen1 BEERSE, Belgium,…
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukaemia
With nearly four years of study follow-up, all-oral, fixed-duration IMBRUVICA® (ibrutinib) + venetoclax reduced the…
Janssen Presents New Data for Talquetamab, a GPRC5DxCD3 Bispecific Antibody, Showing Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
Results from the pivotal MonumenTAL-1 study, including first results from the Phase 2 portion, featured…
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this…
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML ––…